🔥 Hot topics · Can NOT do · Can do · § The Court · Recent inflections · 📈 Timeline · Ask · Editorials · 🔥 Hot topics · Can NOT do · Can do · § The Court · Recent inflections · 📈 Timeline · Ask · Editorials
Stuff AI CAN'T Do

Can AI replace 50% of all drug discovery research by autonomously designing and testing new molecules in silico using generative ai and quantum computing simulations ?

What do you think?

Could generative AI paired with quantum simulations autonomously design and test half of all new drug molecules entirely in silico? The technology already accelerates early-stage discovery, but fully replacing human-led research hinges on closing critical gaps in accuracy, scalability, and validation.

Background

Generative AI can today propose novel small-molecule structures with high predicted binding affinity to protein targets, and in-silico high-throughput screening on classical hardware already covers millions of candidates. However, fully autonomous, end-to-end discovery that combines generative design, quantum-grade docking, and lab validation remains out of reach: docking accuracy is still below the ~1 kcal/mol uncertainty needed for reliable affinity ranking, quantum simulations for large proteins are error-prone on near-term devices, and wet-lab synthesis/validation bottlenecks persist. Current demonstrations achieve partial automation (design → in-silico triage → partial synthesis), but no group has reached the 50% throughput reduction threshold across a broad set of targets. SOURCE: McKinsey & Company — https://www.mckinsey.com/capabilities/quantumblack/our-insights/quantum-computing-in-drug-discovery

Status last checked on June 25, 2026.

📰

Gallery

In the Court of AI Capability
Summary of Findings
Verdict over time
May 2026May 2026May 2026May 2026May 2026Jun 2026Jun 2026Jun 2026Jun 2026Jun 2026
Sitting at the Bench Filed · Jun 25, 2026
— The Question Before the Court —

Can AI replace 50% of all drug discovery research by autonomously designing and testing new molecules in silico using generative ai and quantum computing simulations?

★ The Court Finds ★
▲ Upgraded from In_research
Almost

Narrow demos exist — but the panel was not unanimous.

Ruling of the Bench

The jury acknowledged Generative AI’s impressive strides in molecular design but drew a clear line at quantum computing’s current limitations for autonomous, large-scale testing, leaving room for optimism yet stopping short of full endorsement. The split between two “Almosts” revealed a shared belief in progress but a collective hesitation to declare victory before the hardware and simulation fidelity mature. The ruling: “AI draws the blueprints; quantum must still learn to read the scale.”

— Hon. M. Lovelace, Presiding
Jury Tally
0Yes
2Almost
0No
Verdict Confidence
75%
The Court of AI Capability is, of course, not a real court.
But the data is real.
The Case File · Stacked History
Session I · May 2026 No
Session II · May 2026 Almost · 78%
Session III · May 2026 Almost · 78%
Session IV · May 2026 Almost · 75%
Session V · May 2026 In_research · 77%
Session VI · Jun 2026 Almost · 79%
Session VII · Jun 2026 In_research · 77%
Session VIII · Jun 2026 Almost · 72%
Session IX · Jun 2026 In_research · 85%
Case № AE26 · Session X
In the Court of AI Capability

The Case File

Docket № AE26 · Session X · Vol. X
I. Particulars of the Case
Question put to the courtCan AI replace 50% of all drug discovery research by autonomously designing and testing new molecules in silico using generative ai and quantum computing simulations?
SessionX (10 hearing)
Convened25 Jun 2026
Previously ruledNO (May '26) → ALMOST (May '26) → ALMOST (May '26) → ALMOST (May '26) → IN_RESEARCH (May '26) → ALMOST (Jun '26) → IN_RESEARCH (Jun '26) → ALMOST (Jun '26) → IN_RESEARCH (Jun '26) → ALMOST (Jun '26)
Presiding JudgeHon. M. Lovelace
II. Cumulative Tally Across Sessions

Across 10 sessions, 31 jurors have heard this case. Combined tally: 0 YES · 24 ALMOST · 7 NO · 0 IN RESEARCH.

Note: cumulative includes older juror opinions. The current session tally above is the live verdict.

III. Verdict

By a vote of 0 — 2 — 0, the panel returns a verdict of ALMOST, with verdict confidence of 75%. The court so orders. Verdict upgraded from prior session.

IV. Statements from the Bench
Juror I ALMOST

"Generative AI designs molecules but quantum simulations for molecular testing are not yet autonomous or reliable at scale"

Juror II ALMOST

"Generative AI designs molecules, quantum computing simulates properties"

M. Lovelace
Presiding Judge
M. Lovelace
Clerk of the Court

What the audience thinks

No 62% · Yes 19% · Maybe 19% 26 votes
No · 62%
Yes · 19%
Maybe · 19%
18 days of activity

Discussion

no comments

Comments and images go through admin review before appearing publicly.

10 jury checks · most recent 3 days ago
25 Jun 2026 2 jurors · undecided, undecided undecided
19 Jun 2026 2 jurors · undecided, cannot undecided
14 Jun 2026 3 jurors · undecided, undecided, undecided undecided
08 Jun 2026 2 jurors · cannot, undecided undecided
03 Jun 2026 4 jurors · undecided, cannot, undecided, undecided undecided
29 May 2026 2 jurors · cannot, undecided undecided
23 May 2026 4 jurors · undecided, undecided, undecided, undecided undecided
18 May 2026 4 jurors · undecided, undecided, undecided, undecided undecided
14 May 2026 5 jurors · undecided, undecided, undecided, undecided, undecided undecided status changed
12 May 2026 3 jurors · cannot, cannot, cannot cannot status changed

Each row is a separate jury check. Jurors are AI models (identities kept neutral on purpose). Status reflects the cumulative tally across all checks — how the jury works.

More in biology

Got one we missed?

Add a statement to the atlas. We review weekly.